
    
      This clinical trial will evaluate the efficacy and safety include adverse events, vital
      signs, laboratory tests, etc., of chiauranib added to chemotherapy (Paclitaxel/Etoposide) in
      patients with relapsed or refractory epithelial ovarian, fallopian tube or primary peritoneal
      cancer, in the meantime, explore the pharmacokinetics characteristic after the combined
      treatment.
    
  